36 min listen
Which Endpoints Matter Most in Transthyretin Amyloid Cardiomyopathy Trials? Are We Comparing Apples to Apples?
Which Endpoints Matter Most in Transthyretin Amyloid Cardiomyopathy Trials? Are We Comparing Apples to Apples?
ratings:
Length:
16 minutes
Released:
Mar 26, 2024
Format:
Podcast episode
Description
Do you know how to interpret the results of recent phase 3 clinical trials in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)? Credit available for this activity expires: 3/22/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000444?ecd=bdc_podcast_libsyn_mscpedu
Released:
Mar 26, 2024
Format:
Podcast episode
Titles in the series (100)
Acute Myeloid Leukemia Beyond FLT3 and IDH: The Role of Non-Targetable Driver Mutations: Do you understand the role of non-targetable driver mutations in the management of acute myeloid leukemia (AML)? Credit available for this activity expires: 5/1/2024 Earn Credit / Learning Objectives & Disclosures: by Keeping Current CME